Envíos recientes

Tumor-Associated Microbiome: Where Do We Stand?

Oliva, Marc; Mulet Margalef, Núria; Ochoa de Olza Amat, Maria; Napoli, Stefania; Mas Lloret, Joan; Laquente, Berta; Nuciforo, Paolo Giovanni (Fecha de publicación: 2022-06-17)

Dysbiosis; Gut microbiome; Tumor

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Chaib, Selim; Lopez-Dominguez, Jose Alberto; Lalinde Gutiérrez, Marta; Prats, Neus; Marin Guillen, Ines; Boix Sánchez, Olga; Pérez Ramos, Sandra; Escorihuela Baez, Marta; Garcia-Garijo, Andrea; Abad, Maria; Gros, Alena; Arribas, Joaquin (Fecha de publicación: 2024-03-27)

Chemotherapy; Intratumoral senescent cells

Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project

Groen - van Schooten, Tessa Suzanne; Martinez Ciarpaglini, Carolina; Castillo, Ester; Ruiz-Garcia, Erika; Alsina, Maria; Ruiz Pace, Fiorella; Vivancos, Ana; Matito, Judit; Martin Casado, Agatha; Gómez-Rey, Marina; Vila-Casadesús, Maria; Díez García, Marc; Dienstmann, Rodrigo (Fecha de publicación: 2025-04-07)

Gastric cancer; Gastric cancer biomarkers; Precision medicine

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

Wang, Yifan; Bernhardy, Andrea J.; Nacson, Joseph; Krais, John J.; Tan, Yin-Fei; Nicolas, Emmanuelle; Llop Guevara, Alba; Balmaña Gelpí, Judith; Serra Elizalde, Violeta (Fecha de publicación: 2021-04-13)

Resistència terapèutica contra el càncer; Càncer d'ovaris

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Compadre, Amanda; van Biljon, Lillian; Valentine, Mark; Graham, Emily; Fashemi, Bisiayo; Herencia Ropero, Andrea; Llop-Guevara, Alba; Serra, Violeta (Fecha de publicación: 2023-08-10)

Biomarker predictive; Chemotherapy; Ovarian cancer

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Johnston, Stephen RD; Hegg, Roberto; Martin, Miguel; Shao, Zhi Min; Cortés Castan, Javier; Toi, Masakazu; Harbeck, Nadia (Fecha de publicación: 2021-09-13)

Càncer de mama precoç; Teràpia endocrina; Abemaciclib

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Corti, Chiara; Cortés Castan, Javier; Mittendorf, Elizabeth; Schmid, Peter; Rugo, Hope; Tarantino, Paolo (Fecha de publicación: 2022-07-20)

Breast cancer; Drug development; Immunoediting

Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer

Zunder, Stéphanie M.; Pérez López, Raquel; de Kok, Bente M.; Raciti, Maria Vittoria; van Pelt, Gabi W.; Garcia Ruiz, Alonso; Nuciforo, Paolo Giovanni; Dienstmann, Rodrigo (Fecha de publicación: 2021-10-29)

Imatges per ressonància magnètica; Neoplàsies rectals; Microambient tumoral

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications

Lundberg, Ante S.; Geuijen, Cecile A. W.; Hill, Sally; Lammerts van Bueren, Jeroen J.; Fumagalli, Arianna; de Kruif, John; Tabernero, Josep (Fecha de publicación: 2025-08-12)

EGFR protein; Bispecific antibody; Colorectal cancer

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Mateo Valderrama, Joaquim; Porta, Nuria; Bianchini, Diletta; McGovern, Ursula; Elliott, Tony; Jones, Robert (Fecha de publicación: 2021-08-20)

Prostate cancer; Olaparib; Gene aberrations

The impact of a high fat diet and platelet activation on pre-metastatic niche formation

Hergueta-Redondo, Marta; Sánchez-Redondo, Sara; Hurtado, Begoña; Santos, Vanesa; Pérez-Martínez, Manuel; Ximénez-Embún, Pilar (Fecha de publicación: 2025-05-07)

Fat diet; Platelet activation; Pre-metastatic niche formation

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series

Thorne, Eleanor; O'Connor, Miriam; Elez, Elena; Hardy, Claire; KAMPOSIORAS, KONSTANTNOS; Punie, Kevin (Fecha de publicación: 2025-04-29)

COVID-19; Oncologists; Bell-being

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

Trapani, Dario; Loibl, Sibylle; Senkus, Elzbieta; Criscitiello, Carmen; Cortés Castan, Javier; Delaloge, Suzette; de Azambuja, Evandro (Fecha de publicación: 2021-09-20)

COVID-19; Recomanacions adaptades per l'ESMO; Càncer de mama

A framework for artificial intelligence in cancer research and precision oncology

Perez-Lopez, Raquel; Reis-Filho, Jorge S.; Kather, Jakob Nikolas (Fecha de publicación: 2023-06-20)

Artificial intelligence; Precision oncology

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

Cortés Castan, Javier; Provencher, Louise; Miller, Kathy; Chien, A. Jo; Rugo, Hope; Wardley, Andrew (Fecha de publicación: 2021-06-30)

Receptor d’andrògens; HER2; Càncer de mama metastàsic

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]

DeMichele, Angela; Dueck, Amylou C.; Martín Jiménez, Miguel; Burstein, Harold; Pfeiler, Georg; Hlauschek, Dominik; Bellet Ezquerra, Meritxell (Fecha de publicación: 2025-03-17)

Adjuvant; CDK4/6 inhibitor; Stage II breast cancer

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

de la Cruz-Merino, Luis; Gion, María; Alonso Romero, José Luis; Quiroga, Vanesa; Moreno, Fernando; Cortés Castan, Javier; Cruz, Josefina (Fecha de publicación: 2022-12-28)

Advanced breast cancer; Chemotherapy; Pembrolizumab

Articles científics - VHIO: Envíos recientes

Tumor-Associated Microbiome: Where Do We Stand?

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

The impact of a high fat diet and platelet activation on pre-metastatic niche formation

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

A framework for artificial intelligence in cancer research and precision oncology

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

The importance of data transformation in RNA-Seq preprocessing for bladder cancer subtyping

Microsurgery in pediatric upper limb reconstructions: An overview

Articles científics - VHIO: Envíos recientes

Tumor-Associated Microbiome: Where Do We Stand? ﻿

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2 ﻿

Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project ﻿

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance ﻿

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer ﻿

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) ﻿

Immunotherapy for early triple negative breast cancer: research agenda for the next decade ﻿

Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer ﻿

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications ﻿

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial ﻿

The impact of a high fat diet and platelet activation on pre-metastatic niche formation ﻿

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series ﻿

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer ﻿

A framework for artificial intelligence in cancer research and precision oncology ﻿

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer ﻿

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13] ﻿

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study ﻿

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer ﻿

The importance of data transformation in RNA-Seq preprocessing for bladder cancer subtyping ﻿

Microsurgery in pediatric upper limb reconstructions: An overview ﻿

Tumor-Associated Microbiome: Where Do We Stand?

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

The impact of a high fat diet and platelet activation on pre-metastatic niche formation

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

A framework for artificial intelligence in cancer research and precision oncology

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

The importance of data transformation in RNA-Seq preprocessing for bladder cancer subtyping

Microsurgery in pediatric upper limb reconstructions: An overview